Site Editor

Leo I. Gordon, MD, FACP


Safety and Efficacy of Blinatumomab for Patients With High-Risk DLBCL

By: Justine Landin, PhD
Posted: Monday, August 29, 2022

The CD19-positive cell-targeting immunomodulator blinatumomab may be promising for high-risk patients with diffuse large B-cell lymphoma (DLBCL), according to a phase II study conducted by Deborah A. Katz, MD, of Rush University Medical Center, Chicago, and colleagues. In fact, the majority of patients who achieved a partial response or stable disease following chemotherapy achieved a complete response after administration of blinatumomab. The findings of this open-label, multicenter, single-arm study were published in the journal Leukemia and Lymphoma.

“Consolidation with blinatumomab therapy following induction with R-chemotherapy in patients with newly diagnosed, high-risk [DLBCL] was better tolerated with no new safety signals compared with previous studies in patients with relapsed or refractory lymphomas,” stated the study investigators.

Adult patients with newly diagnosed, high-risk DLBCL and an International Prognostic Index score of 3 to 5, and/or doubt-hit/triple-hit disease, and/or double protein expression of MYC and BCL-2 with an Eastern Cooperative Oncology Group performance status of 2 or less were enrolled (n = 47). Patients were separated into groups based upon whether they had achieved a complete response, a partial response, or stable disease 3 weeks following six rounds of R-chemotherapy. Patients were assigned to receive continuous blinatumomab via intravenous infusion for a single 84-day cycle (n = 28), or they received no blinatumomab treatment (n = 19).

Blinatumomab appeared to be well tolerated, with only five patients (17.9%) experiencing grade 4 adverse events: four cases of neutropenia and one of infection. Following blinatumomab treatment, 75% of patients in the partial response group and 100% of patients in the stable disease group achieved a complete response. There were two deaths during the course of the study, but they were due to disease progression or infection and were unrelated to blinatumomab treatment.

Disclosure: For full disclosures of the study authors, visit

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.